This story originally appeared in Biocommerce Week, a newsletter that has been discontinued.
 
Waters this week reported its fourth consecutive quarter of double-digit revenue growth, which company officials attributed primarily to a continuing increase in demand for instruments from large pharma customers, with a particular emphasis on new systems.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.